Donor screening for hepatitis B virus infection in a cell and tissue bank

Abstract: Background and objectives. Hepatitis B virus (HBV) has been transmitted by tissue transplantation. In order to reduce the risk of HBV transmission, testing for antibody to HBV core antigen (anti‐HBc) is used in addition to testing for hepatitis B surface antigen (HBsAg) in many blood centers and tissue banks.

[1]  P. Gallian,et al.  Occult hepatitis B infection in blood donors , 2008, Vox sanguinis.

[2]  M. Rizzetto,et al.  Italian blood donors with anti-HBc and occult hepatitis B virus infection , 2007, Haematologica.

[3]  R. Villalba,et al.  Evaluation of tissue discards after implementation of anti-HBc test in a tissue bank in Spain , 2007, Cell and Tissue Banking.

[4]  K. Radsak,et al.  Introduction of anti‐HBc testing of blood donors in Germany , 2006, Transfusion medicine.

[5]  C. Lucey.  Brief report on the United States Food and Drug Administration Blood Products Advisory Committee recommendations for management of donors and units testing positive for hepatitis B virus DNA , 2006, Vox sanguinis.

[6]  P. Holland,et al.  Hepatitis B virus blood screening: unfinished agendas , 2006, Vox sanguinis.

[7]  A. Zanetti,et al.  Changing patterns of hepatitis B infection in Italy and NAT testing for improving the safety of blood supply. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  A. Zanetti,et al.  Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study , 2005, The Lancet.

[9]  J. Colomina-Rodríguez,et al.  Significado de la reactividad aislada anti-HBc como único marcador de infección de la hepatitis B , 2005 .

[10]  S. Stramer,et al.  Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. , 2004, The New England journal of medicine.

[11]  M. Busch,et al.  Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? , 2004, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[12]  J. Allain.  Occult hepatitis B virus infection. , 2004, Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine.

[13]  J. Allain,et al.  Occult hepatitis B virus infection: implications in transfusion , 2004, Vox sanguinis.

[14]  J. Hernández,et al.  Estimated risk of transfusion‐transmitted viral infections in Spain , 2002, Transfusion.

[15]  R. Dodd.  Current viral risks of blood and blood products , 2000, Annals of medicine.

[16]  R. Tedder,et al.  Evidence that anti‐HBc but not HBV DNA testing may prevent some HBV transmission by transfusion , 1999, British journal of haematology.

[17]  D. Lavanchy,et al.  Seroprevalence of HBV (anti-HBc, HBsAg and anti-HBs) and HDV infections among 9006 women at delivery. , 2008, Liver.

[18]  G. Hetland,et al.  Posttransfusion hepatitis B transmitted by blood from a hepatitis B surface antigen‐negative hepatitis B virus carrier , 1990, Transfusion.

[19]  B. Blumberg.  Australia antigen and the biology of hepatitis B. , 1977, Science.